Dr Fiona Kerr F.Kerr@napier.ac.uk
Lecturer
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease
Kerr, Fiona; Sofola-Adesakin, Oyinkan; Ivanov, Dobril K.; Gatliff, Jemma; Gomez Perez-Nievas, Beatriz; Bertrand, Hélène C.; Martinez, Pedro; Callard, Rebecca; Snoeren, Inge; Cochemé, Helena M.; Adcott, Jennifer; Khericha, Mobina; Castillo-Quan, Jorge Iván; Wells, Geoffrey; Noble, Wendy; Thornton, Janet; Partridge, Linda
Authors
Oyinkan Sofola-Adesakin
Dobril K. Ivanov
Jemma Gatliff
Beatriz Gomez Perez-Nievas
Hélène C. Bertrand
Pedro Martinez
Rebecca Callard
Inge Snoeren
Helena M. Cochemé
Jennifer Adcott
Mobina Khericha
Jorge Iván Castillo-Quan
Geoffrey Wells
Wendy Noble
Janet Thornton
Linda Partridge
Abstract
Nrf2, a transcriptional activator of cell protection genes, is an attractive therapeutic target for the prevention of neurodegenerative diseases, including Alzheimer’s disease (AD). Current Nrf2 activators, however, may exert toxicity and pathway over-activation can induce detrimental effects. An understanding of the mechanisms mediating Nrf2 inhibition in neurodegenerative conditions may therefore direct the design of drugs targeted for the prevention of these diseases with minimal side-effects. Our study provides the first in vivo evidence that specific inhibition of Keap1, a negative regulator of Nrf2, can prevent neuronal toxicity in response to the AD-initiating Aβ42 peptide, in correlation with Nrf2 activation. Comparatively,
lithium, an inhibitor of the Nrf2 suppressor GSK-3, prevented Aβ42 toxicity by mechanisms independent of Nrf2. A new direct inhibitor of the Keap1-Nrf2 binding domain also prevented synaptotoxicity mediated by naturally-derived Aβ oligomers in mouse cortical
neurons. Overall, our findings highlight Keap1 specifically as an efficient target for the reactivation of Nrf2 in AD, and support the further investigation of direct Keap1 inhibitors for the prevention of neurodegeneration in vivo.
Citation
Kerr, F., Sofola-Adesakin, O., Ivanov, D. K., Gatliff, J., Gomez Perez-Nievas, B., Bertrand, H. C., Martinez, P., Callard, R., Snoeren, I., Cochemé, H. M., Adcott, J., Khericha, M., Castillo-Quan, J. I., Wells, G., Noble, W., Thornton, J., & Partridge, L. (2017). Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease. PLOS Genetics, 13(3), Article e1006593. https://doi.org/10.1371/journal.pgen.1006593
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 6, 2017 |
Online Publication Date | Mar 2, 2017 |
Publication Date | Mar 2, 2017 |
Deposit Date | Mar 3, 2017 |
Publicly Available Date | Mar 9, 2017 |
Journal | PLOS Genetics |
Print ISSN | 1553-7390 |
Electronic ISSN | 1553-7404 |
Publisher | Public Library of Science |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 3 |
Article Number | e1006593 |
DOI | https://doi.org/10.1371/journal.pgen.1006593 |
Public URL | http://researchrepository.napier.ac.uk/Output/692163 |
Contract Date | Mar 3, 2017 |
Files
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease
(6.5 Mb)
PDF
Copyright Statement
Copyright: © 2017 Kerr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
You might also like
Increased Glucose Transport into Neurons Rescues Aβ Toxicity in Drosophila
(2016)
Journal Article
Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis
(2016)
Journal Article
Deletion of endogenous Tau proteins is not detrimental in Drosophila
(2016)
Journal Article
Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
(2010)
Journal Article
Downloadable Citations
About Edinburgh Napier Research Repository
Administrator e-mail: repository@napier.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search